Last reviewed · How we verify
Human Rabies Immune Globulin
At a glance
| Generic name | Human Rabies Immune Globulin |
|---|---|
| Also known as | Human Rabies Immune Globulin produced by Thai Red Cross |
| Sponsor | Queen Saovabha Memorial Institute |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- Washington University WU 409: Immune Responses to Rabies Vaccine. (EARLY_PHASE1)
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- SYN023 With Rabies Vaccine in Healthy Pediatric Subjects (PHASE1)
- Survey of Human Rabies Immune Globulin Safety in Children
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Rabies Immune Globulin CI brief — competitive landscape report
- Human Rabies Immune Globulin updates RSS · CI watch RSS
- Queen Saovabha Memorial Institute portfolio CI